NPC-REAAD™ is an in-vitro diagnostic intended for qualitative and semi-qualitative detection of IgA antibodies in human serum samples for nasopharyngeal carcinoma.
It uses proprietary proteins developed by Restalyst to identify specific IgA antibody to EA seromarker segment.
Detection of EA is associated with higher specificity in comparison to other EBV related markers, resulting in fewer false positive during screening. This is particularly important and is a feature that our customers especially value with NPC-REAAD™. Fewer false positive results reduce unnecessary worry to patients and the requirement for them to undergo unnecessary procedures or treatments.
GC-REAAD™ is an in-vitro diagnostic intended for early detection of gastric carcinoma using a patented biomarker. This biomarker was discovered to be expressed at high levels in the patients plasma samples. Additionally, risk factor for gastric cancer like Helicobacter pylori (H. pylori) infection, does not influence the biomarkers expression levels within plasma.
The competition between the patented biomarker and its specific antibodies is the gist of how GC-REAAD™ functions. Positive or negative results obtained through calculations help to determine the patients status of gastric cancer.
HCC-REAADTM is an in-vitro diagnostic intended for early detection of hepatocellular carcinoma using a patented biomarker. Elevated levels of this biomarker were identified within hepatocellular carcinoma patients plasma. Internal research studies by Restalyst indicated that this patented biomarker produces better sensitivity than AFP.